William Boyle

Dr. Bill Boyle has 28 years of experience as a senior executive in the pharmaceutical and biotech industry. That experience has ranged across a number of different companies including Amgen and AnaptysBio. Dr. Boyle has extensive experience in monoclonal antibody discovery and development. He was the Founder and Former CSO of AnaptysBio, which had an IPO in 2017. He led the discovery and characterization of Denosumab as the Director of Research at Amgen. He was an Associate Professor of Medicine at UCLA David Geffen School of Medicine and Director of DGSOM CTSI Accelerator.